Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMO | Q99835 | 3/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839464 | 0.85 | KCNH2 (0.48) | MEN1KMT2ASMOKCNH2MAPT | |
| SCHEMBL12082286 | 0.82 | KMT2A (0.67) | MEN1KMT2AHSD11B1MAPTMAPK1 | |
| SCHEMBL975607 | 0.75 | SMO (0.43) | MEN1KMT2ASMOKCNH2MAPT | |
| SCHEMBL23544827 | 0.75 | ALDH1A1 (0.48) | SMOKCNH2MAPTTP53THRB | |
| SCHEMBL23446066 | 0.75 | JAK3 (0.45) | MEN1KMT2ASMOTP53THRB | |
| SCHEMBL3664917 | 0.74 | THRB (0.45) | MEN1KMT2AHSD11B1MAPTTP53 | |
| SCHEMBL13591219 | 0.74 | MEN1 (0.69) | MEN1KMT2AHSD11B1MAPTMAPK1 | |
| SCHEMBL82680 | 0.74 | MEN1 (0.69) | MEN1KMT2AHSD11B1MAPTTHRB | |
| SCHEMBL8350747 | 0.73 | MAPT (0.58) | MAPTPOLB | |
| SCHEMBL17039352 | 0.72 | L3MBTL1 (0.45) | SMOMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | MEN1 4006/4885KMT2A 2231/4885SMO 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.